Curacle Seeks FDA Approval for Phase 2b Trial of CU06 in Diabetic Macular Edema

PUBT · 1d ago
Curacle Seeks FDA Approval for Phase 2b Trial of CU06 in Diabetic Macular Edema
  • Curacle applied to the FDA on Nov. 20, 2026, for a Phase 2b trial of CU06-1004 for diabetic macular edema.
  • The U.S. trial targets 156 patients to evaluate efficacy and safety over 24 weeks, helping determine dosing for Phase 3.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curacle Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261120900267), on November 20, 2026, and is solely responsible for the information contained therein.